RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) ahead of data from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE